These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38679232)

  • 1. A Review on Commercial Oligonucleotide Drug Products.
    Vinjamuri BP; Pan J; Peng P
    J Pharm Sci; 2024 Jul; 113(7):1749-1768. PubMed ID: 38679232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense drug discovery and development technology considered in a pharmacological context.
    Crooke ST; Liang XH; Crooke RM; Baker BF; Geary RS
    Biochem Pharmacol; 2021 Jul; 189():114196. PubMed ID: 32800852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of Formulations of Commercially Available Antibodies.
    Strickley RG; Lambert WJ
    J Pharm Sci; 2021 Jul; 110(7):2590-2608.e56. PubMed ID: 33789155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
    Migliorati JM; Liu S; Liu A; Gogate A; Nair S; Bahal R; Rasmussen TP; Manautou JE; Zhong XB
    Drug Metab Dispos; 2022 Jun; 50(6):888-897. PubMed ID: 35221287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of antisense oligonucleotide and siRNA-based therapeutics.
    Chi X; Gatti P; Papoian T
    Drug Discov Today; 2017 May; 22(5):823-833. PubMed ID: 28159625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Container Closure and Delivery Considerations for Intravitreal Drug Administration.
    Parenky AC; Wadhwa S; Chen HH; Bhalla AS; Graham KS; Shameem M
    AAPS PharmSciTech; 2021 Mar; 22(3):100. PubMed ID: 33709236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis.
    Niemietz C; Chandhok G; Schmidt H
    Molecules; 2015 Sep; 20(10):17944-75. PubMed ID: 26437390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioconjugated Oligonucleotides: Recent Developments and Therapeutic Applications.
    Benizri S; Gissot A; Martin A; Vialet B; Grinstaff MW; Barthélémy P
    Bioconjug Chem; 2019 Feb; 30(2):366-383. PubMed ID: 30608140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular dynamics simulation and binding energy calculation for estimation of oligonucleotide duplex thermostability in RNA-based therapeutics.
    Shen L; Johnson TL; Clugston S; Huang H; Butenhof KJ; Stanton RV
    J Chem Inf Model; 2011 Aug; 51(8):1957-65. PubMed ID: 21702481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re-Engineering RNA Molecules into Therapeutic Agents.
    Egli M; Manoharan M
    Acc Chem Res; 2019 Apr; 52(4):1036-1047. PubMed ID: 30912917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of modified antisense oligonucleotides and siRNAs as antiviral drugs.
    Wagner A; Bock CT; Fechner H; Kurreck J
    Future Med Chem; 2015; 7(13):1637-42. PubMed ID: 26381598
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical Pharmacology of RNA Interference-Based Therapeutics: A Summary Based on Food and Drug Administration-Approved Small Interfering RNAs.
    Jing X; Arya V; Reynolds KS; Rogers H
    Drug Metab Dispos; 2023 Feb; 51(2):193-198. PubMed ID: 36332914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense technology: A review.
    Crooke ST; Liang XH; Baker BF; Crooke RM
    J Biol Chem; 2021; 296():100416. PubMed ID: 33600796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense technology: an overview and prospectus.
    Crooke ST; Baker BF; Crooke RM; Liang XH
    Nat Rev Drug Discov; 2021 Jun; 20(6):427-453. PubMed ID: 33762737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Click conjugated polymeric immuno-nanoparticles for targeted siRNA and antisense oligonucleotide delivery.
    Chan DP; Deleavey GF; Owen SC; Damha MJ; Shoichet MS
    Biomaterials; 2013 Nov; 34(33):8408-15. PubMed ID: 23932248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic delivery and pre-clinical evaluation of nanoparticles containing antisense oligonucleotides and siRNAs.
    Zhang C; Newsome JT; Mewani R; Pei J; Gokhale PC; Kasid UN
    Methods Mol Biol; 2009; 480():65-83. PubMed ID: 19085118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyamine-oligonucleotide conjugates: a promising direction for nucleic acid tools and therapeutics.
    Menzi M; Lightfoot HL; Hall J
    Future Med Chem; 2015; 7(13):1733-49. PubMed ID: 26424049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense oligonucleotides: absorption, distribution, metabolism, and excretion.
    Shadid M; Badawi M; Abulrob A
    Expert Opin Drug Metab Toxicol; 2021 Nov; 17(11):1281-1292. PubMed ID: 34643122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small Drugs, Huge Impact: The Extraordinary Impact of Antisense Oligonucleotides in Research and Drug Development.
    Quemener AM; Centomo ML; Sax SL; Panella R
    Molecules; 2022 Jan; 27(2):. PubMed ID: 35056851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Site Selective Antibody-Oligonucleotide Conjugation via Microbial Transglutaminase.
    Huggins IJ; Medina CA; Springer AD; van den Berg A; Jadhav S; Cui X; Dowdy SF
    Molecules; 2019 Sep; 24(18):. PubMed ID: 31509944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.